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This study aimed to investigate the effect of polydatin against thrombosis and its possible mechanisms. 
The methods of injection of arachidonic acid into mouse tail vein electrically stimulated carotid 
thrombosis in rats, and the rats’ inferior vena ligation were used to evaluate the antithrombotic effects 
of polydatin. Platelet aggregation was tested by use of Born’s method, and platelet cytosolic calcium 
was determined by use of Fura-2/AM. Thromboxane B2 and 6-keto-prostaglandin F1 level was 
monitored by the immuno-assay, while Rosette assay and Born’s method were used to observe platelet-
neutrophil interactions. The results show that polydatin had evident antithrombotic effects in the 
multiple-thrombosis models; the mechanisms may be closely related to its anti-platelet aggregation, 
which results in decrease of platelet cytosolic calcium and plasma thromboxane B2, while increasing 
plasma 6-keto-prostaglandin F1 Level and suppressing of platelet-neutrophil interactions.  
 





Modern researches show that the process of thrombosis 
is closely related with interactions of platelets, leukocytes 
and other cells. Activated platelets can release some 
active substances including platelet activating factor 
(PAF) and thromboxane. Such active substances activate 
polymorphonuclear leukocytes (PMN), and activated 
PMNs accelerate the expression of platelet selectin so 
that adhesion between PMNs and platelets occurs while 
producing more thromboxane and promoting the 
mobilization of platelet intracellular calcium (Armstrong et 
al., 2008; Chlopicki et al., 2003). Therefore, an obvious 
platelet aggregation is induced, which results in accele-
ration of the process of thrombosis eventually. 
Thromboembolic diseases are great threats to human’s 
life and health and prevention and treatment of throm-
bosis is a focus of modern medical research. One of the 
new hopes in this field of disease may be found in high 
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trihydroxystilbene-3-beta-D-glucopyranoside, Figure 1), a 
glucoside of resveratrol, is widely distributed in many 
plants especially in Polygonum cuspidatum and shows 
protective effects against hyperlipemia and ischemia/ 
reperfusion injury (Xing et al., 2009; Zhang et al., 2008; 
Huang et al., 2003; Du et al., 2009). Hence, its 
pharmacological effects in cardiovascular fields are to 
attract broad attention in recent years. 
Platelet hyperfunction and abnormality in thromboxane 
A2 (TXA2) and prostacyclin equilibrium is closely related 
to thrombosis and TXA2 is a mediator of the sudden 
death induced by intravenous arachidonate in mice. AA, 
as a substrate of cyclooxygenase (COX), is transformed 
to two unstable intermediate products - prostaglandin G2 
(PGG2) and prostaglandin H2 (PGH2). PGG2 and PGH2 
can form TXA2 through the action of thromboxane 
synthetase and an increase of TXA2 will result in the 
adhesion, aggregation and release of platelets. PGG2 and 
PGH2 can also form prostacyclin I2 (PGI2) through the 
action of prostacyclin synthetase and the PGI2 is able to 
inhibit platelet aggregation. Accordingly, drugs’ inhibition 
on the metabolism of AA is likely to inhibit the activity of 
COX or affect the activities of thromboxane synthetase or  
 
  










prostacyclin synthetase (Gross and Moore, 2004). The 
biological half-life of TXA2 and PGI2 are about 30 s and 3 
min, respectively, then they turn into TXB2 and 6-keto-
PGF1 rapidly. Thus, the determination of TXB2 and 6-
keto-PGF1 is used as a chief means of estimating the 
levels of TXA2 and PGI2 (Terashita et al., 1995). 
Electrical stimulation on rat carotid artery can injure vas 
endodermis, activates platelets and neutrophils, induce 
platelet aggregation and finally leads to a mixed 
thrombus. This experiment is to investigate antithrombotic 
effect of polydatin by the use of multiple arterial and 
venous thrombosis models and to explore its antithrom-
botic mechanisms by detecting the effects of polydatin on 
platelets, neutrophils, thromboxane B2 (TXB2), 6-keto-
prostaglandin F1, and platelet cytosolic calcium, in view 
of providing more detailed bases for curing thrombotic 
diseases with polydatin.  
 
 
MATERIALS AND METHODS 
 
Drugs and reagent  
 
The rhizomatic parts of P. cuspidatum were obtained in Yunnan 
Province of China. The plant was identified by Prof. Renwei Zhang 
(Yunnan Institute of Materia Medica) and a voucher specimen is 
deposited in the herbarium collection of the Institute (Yun. No. 
025618). The medicinal materials were extracted with alcohol and 
the filtrates were extracted by ethyl acetate. The extracts were 
concentrated and separated on macroporous resin and Al2O3 
column. High performance liquid chromatography (HPLC) was used 
for quantitative analysis of the obtained polydatin (molecular 
formula C20H22O8, molecular weight 390.40, purity 99%).  
Polydatin was dissolved in 0.9% saline (pH 7.0) before use. 
Aspirin (Sigma) was dissolved with 100 mmol/L Na2CO3 before use, 
pH7.0. Arachidonic acid (AA) (Sigma) was dissolved in absolute 





diphosphate (ADP) (Fluka) was dissolved in 0.9% saline, pH 7.0. 
Platelet activating factor (PAF) (Sigma) was dissolved in Tris-NaCl 
buffer solution, which involved 0.25% bovine serum albumin (BSA), 
pH7.5. Thrombin (Sigma) was dissolved in 0.9% saline, pH 7.0. N-
formyl-methionyl-leucyl-phenylalanine (fMLP) (Sigma) was 
dissolved in dimethyl sulfoxide and was diluted with distilled water 
before use. Fura-2/AM was from Sigma. The radioimmunoassay 
kits of TXB2 and 6-keto-PGF1 were purchased from ShenKe 





Healthy rabbits weighing 2.0 to 3.0 kg, male Sprague-Dawley (SD) 
rats weighing 250 to 300 g and male ICR mice weighing 22 to 26 g, 
were offered by the Experimental Animal Center of Yunnan Key 
Laboratory of Pharmacology for Natural Products. The protocol of 
this study was approved by the Ethics Committee of Kunming 
Medical University (SCXK2009008). 
 
 
AA caused mouse's death 
 
Male ICR mice were randomly divided into 5 groups of 15 mice 
each. Group A: 0.9 % saline, group B: 10 mg/kg aspirin, and groups 
C to E: 5, 10 and 20 mg/kg polydatin. These 75 male ICR mice 
were no-eating overnight. Morrow, the mice were injected the above 
substances into tail veins. 0.5 h after administration, 80 mg/kg AA 
was intravenously injected into mice's tails at 50 µL / 10 g body 
weight. Myers's method was modified (Myers et al., 1986). After 15 
min, the number of surviving animals in the treatment and control 
groups was counted.  
 
 
Electrically stimulated rat carotid artery thrombosis  
 
SD rats were randomly divided into 5 groups of 10 rats each. Group 
A: 0.9% saline, group B: 10 mg/kg aspirin, and groups C to E: 5, 10, 
and 20 mg/kg polydatin respectively. The rats were anaesthetized 
by 30 mg/kg of sodium amobarbital, and were injected in femoral 
vein with the aforementioned substance. 15 min after 
administration, Charlton's method was modified (Charlton et al., 
1996). The artery was electrically stimulated (1.5 mA for 7 min) 
using an electronic stimulator (model SEN-7203, Nihon Kohden 
Corporation, Japan). The time to the formation of an occlusive 
thrombus (zero arterial flow) was recorded with a Direction Volume 
Meter (model DVM-4200, Hayashi Denki Corporation, Japan). If the 
vessels were still patent at the end of this observation period, the 




Ligated rat inferior vena cava thrombosis 
 
The rats were randomly divided into 5 groups of 10 rats each. 
Group A: 0.9% saline, group B: 10 mg/kg aspirin and groups C to E: 
5, 10 and 20 mg/kg polydatin respectively. The rats were 
anaesthetized by 30 mg/kg of sodium amobarbital. Vein thrombosis 
model were duplicated according to the method described by CX 
Chen (Chen et al., 1992). The rat's abdomen was opened and the 
inferior vena cava was isolated and ligated below the left renal vein 
level, and then the abdomen was closed. After 1 h, the rats were 
injected in femoral vein with the above substance in a volume of 0.1 
mL/ 100 g body weight, respectively. Two hours later, the abdomen 
was reopened. The thrombus in the inferior vena cava was 







then placed in a drying oven at 60°C for 20 h before measuring the 
dry weight.  
 
 
Preparation of platelet (Shen et al., 2003) 
 
Healthy rabbits were used. Blood from rabbit’s carotid artery was 
mixed with one-sixth volume of acid citrate dextrose (sodium citrate 
25, citric acid 15, and D-glucose 20 g/L, for the measurement of 
platelet cytosolic calcium level). This blood was then spun to obtain 
platelet-rich plasma (PRP) at 300 × g for 15 min. PRP was further 
spun at 1000 × g for 10 min to pellet the platelets. Platelet pellets 
were gently suspended in prewarmed Tyrode-HEPES buffer 
(containing NaCl 134, KCl 2.9, NaHCO3 12, NaH2PO4 0.36, MgCl2 
1, glucose 5, HEPES 5 mmol/L and bovine serum albumin 0.35%, 
pH 7.2). After washed twice, the cells were resuspended in the 
above buffer solution. The platelet count was adjusted to about 5 × 
108 cell / L. 
Blood from rabbit carotid artery was collected into plastic tubes, 
anticoagulated with 2.7% of ethylenediaminetetraacetic acid (EDTA) 
(for the binding of platelets to neutrophils) or 3.8% sodium citrate 
acid (for aggregation). This sample was spun for 10 min at 180 × g 
to obtain PRP. PRP was further spun to pellet platelets at 1000 × g 
for 10 min. Platelet pellets were washed three times and 
resuspended in phosphate buffer solution (PBS, containing 1.0% 
bovine serum albumin, 1.4 mmol/L EDTA, and 1 mmol/L CaCl2). 
Cell viability by Typan blue exclusion was above 95 % and cell 
counter was adjusted to 108 cell/mL. 
 
 
Preparation of neutrophils (Shen et al., 2003) 
 
Neutrophils were isolated from the blood (coagulated by 2.7% 
edetic acid, from which platelet-rich plasma was removed). The cell 
pellet was resuspended in an erythrocyte lysis buffer composed of 
155 mmol/L NH4Cl, 2.96 mmol/L KHCO3, and 3.72 mmol/L acetic 
acid. The tube was gently inverted, then after 5 min the suspension 
was centrifuged at 350 × g for 10 min, and the cell pellet was 
washed in PBS lacking calcium; then resuspended in Hanks’ 
solution (containing 1 mmol/L CaCl2 or 5 mmol/L egtazic acid in 
vehicle, reflecting the situation with or without external calcium). 
Cells were adjusted to a count of 2 × 108 cell/mL (for adhesion) or 
0.5 ×106 cell/mL (for platelet aggregation). Cells prepared in this 
manner contained 98% neutrophils and were 96% viable. 
 
 
Platelet aggregation in vitro 
 
Platelets aggregation was determined by Born's methods (Born, 
1962). PRP was further spun at 3000 × g for 15 min to obtain 
platelet-poor plasma (PPP). The maximal aggregation was 
monitored in a Lumiaggregometer (Kemao Limited Company, 
Beijing, China). The final concentrations of ADP, AA and PAF were 
3 µmol/L, 0.35 mmol/L and 7.2 nmol/L, respectively. Percentage 
inhibition by drugs was calculated by use of the following equation: 
 
Inhibition of aggregation (%) = (A - B) / A ×100 
 
Where, A is the maximum change of turbidity when the control 
(saline) is added and B is the maximum change of turbidity when 
the drug (different concentrations of polydatin or aspirin) is added. 
 
 
Platelet aggregation ex vivo 
 
The animals  were  randomly  divided  into  5  groups  of  6   rabbits.  




Group A: 0.9% saline, group B: 10 mg/kg aspirin and groups C to E: 
5, 10, and 20 mg/kg polydatin respectively. Blood sample from 
rabbit carotid artery was collected before administration. PRP and 
PPP were prepared before administration and at 0.5, 1, 1.5, 2, 3 
and 4 h after administration, respectively. Platelet aggregation 




Platelet cytosolic calcium level 
 
Intracellular Ca2+ concentration of platelets was measured by using 
Fura-2-AM with a spectrofluorophotometer (Model RF-5000, 
Shimazhu, Japan) at 37°C and magnetically stirred. The cells were 
treated with 0.1% Triton X-100 followed by the addition of egtazic 
acid 10 mmol/L to obtain the maximal and minimal fluorescence, 
respectively. The ratio of the measured fluorescence values at 340 
and 380 nm excitation was calculated. [Ca2+]i was calculated by the 
method of Grynkiewicz G (Grynkiewicz et al., 1985). AA (200 
µmol/L)-induced rise in [Ca2+]i was measured in the presence of 1 
mmol/L CaCl2 or 1 mmol/L egtazic acid, respectively. 
 
 
Determination of TXB2 and 6-keto-PGF1  
 
Before injection and at 30, 60, 120 min after injection of the drugs, 
rabbit blood from carotid artery was anticoagulated with heparin 
(3.5 mg/mL) and spun at 1000 × g at 0°C for 10 min to obtain 
plasma. TXB2 and 6-keto-PGF1 in plasma were extracted from the 
supernatant and assayed by use of radioimmunoassay kits. 
 
 
Rosette assay (Shen et al., 2004) 
 
The method of Rosette assay was modified. 50 µL of platelets and 
0.2 U/mL thrombin were mixed and incubated for 15 min at 37°C, 
50 µL of drugs were then added and incubated for another 15 min. 
Then 100 µL of neutrophils was added to the platelet suspension. 
One hundred neutrophils were scored for the presence (two or 
more platelets per neutrophil) or absence (zero or one platelet per 
neutrophil) of platelets. Neutrophils bearing two or more platelets 
were thus defined as rosettes. For each assay done in triplicate, the 
rosetting score was assessed by two different observers.  
 
 
Inhibition of platelet aggregation induced by the suspension of 
activated neutrophils  
 
100 µL of platelets (108 cell/mL) were mixed with 100 µL of 
neutrophils (0.5 ×107 cell/mL) and stirred for 2 min at 37°C. 0.9% 
saline or drug solution was added and incubated for 5 min and then 
2 µmol/L of fMLP was added. Platelet aggregation was observed 





The data were analyzed by the software bag of SPSS (Version 13, 
SPSS Inc., USA). All enumeration data were expressed as 
percentages and analyzed by use of Chi-square test. All 
measurement data were expressed as mean ± SD, and 
analyzed by one way ANOVA and least-significant difference 
(LSD) test, respectively. Differences were considered statistically 
significant when P < 0.05. 
 
  




Table 1. Preventive effect of polydatin against mouse sudden death caused by injection of 
arachidonic acid. 
 
Group Dose (mg/kg) Died / Total Mortality (%) 
Saline - 13 / 15 87.0 
Aspirin 10 4 / 15 26.6** 
    
Polydatin 
5 6 / 15 40.0** 
10 3 / 15 20.0** 
20 2 / 15 13.3** 
 
Died: the number of animals that died 15 min after injection of arachidonic acid; Total: the number of 
animals that were used in the study. The mortality was estimated 15 min after injection of AA (80 




Table 2. Effect of polydatin on electrically stimulated carotid arterial thrombosis in rats. 
 
Group Dose (mg/kg) Occlusion time (min) 
Saline    17.6 ± 1.1 
   
Polydatin 
5 29.8 ± 4.7** 
10 31.9 ± 4.7** 
20 37.6 ± 4.1** 
   
Aspirin 10 27.1 ± 2.0** 
 
Values are means ± SD, n = 10, ** P < 0.01, compared with saline. All the substances were 
administered intragastrically. 15 min after administration, the carotid artery was electrically 






Preventive effect of polydatin against mouse sudden 
death caused by injection of AA 
 
Polydatin at 5, 10 and 20 mg/kg had a potent inhibitory 
effect on mouse death as a result of pulmonary thrombi 
induced by AA injection into the tail vein (Table 1).  
 
 
Effect of polydatin on electrically stimulated arterial 
thrombosis in rats  
 
Polydatin at 5, 10 and 20 mg/kg significantly prolonged 
the occlusion time in a dose-dependent manner. The 
reference compound aspirin also delayed the occlusion 
time (Table 2). 
 
 
Effect of polydatin on inferior venous thrombosis in 
rats 
 
In saline group, the wet and dry thrombus weights were 
10.3 ± 1.6 and 4.8 ± 0.8 mg, respectively. Polydatin  at  5, 
10 and 20 mg/kg evidently reduced the wet and dry 
thrombus weight (Table 3). 
 
 
Effects of polydatin on rabbit platelet aggregation in 
vitro 
 
Polydatin concentration-dependently suppressed platelet 
aggregation induced by AA and ADP, but not by PAF. The 
IC50 values were 5.13 for AA and 10.07 µmol/L for ADP, 
respectively (Table 4). 
 
 
Effects of polydatin on rabbit platelet aggregation ex 
vivo 
 
Polydatin at 5, 10 and 20 mg/kg also showed potent 
inhibitory effects on AA or ADP- induced platelet 
aggregation, but had no inhibitory effect on PAF- induced 
platelet aggregation (Table 5). 
 
 
Effect of polydatin on platelet cytosolic calcium level 
 
In the presence of 1 mmol/L CaCl2,  the  resting  cytosolic  
 
  




Table 3. Effect of polydatin on inferior venous thrombosis in rats. 
 
Group Dose (mg/kg) 
Thrombus weight (mg) 
Wet Dry 
Saline - 10.3 ± 1.6 4.8 ± 0.8 
    
Polydatin 
5 5.4 ± 1.0** 1.8 ± 0.7** 
10 3.6 ± 1.1** 1.1 ± 0.4** 
20 1.6 ± 0.9** 0.7 ± 0.2** 
    
Aspirin 10 2.3 ± 0.5** 1.3 ± 0.5** 
 
Values are means ± SD, n = 10, ** P < 0.01, compared with saline. The inferior vena cava was 
isolated and ligated below the left renal vein level. 1 h after ligation, the substances were 
administered through the femoral vein in a volume of 0.1 mL/100 g body weight, respectively. 2 h 
later, the thrombus in the inferior vena cava was collected into a glass dish for measurement of wet 
weight. It was then placed in a drying oven at 60°C for 20 h before measuring the dry weight. 
 
 
Table 4. Effects of polydatin on rabbit platelet aggregation induced by AA, ADP and PAF in vitro. 
 
Group Dose (µmol/L) 
Inhibition of platelet aggregation (%) 
AA ADP PAF 
Polydatin 
4.7 49.8 ± 5.9** 36.5 ± 3.6** 1.3 ± 1.0 
9.4 63.8 ± 8.9** 42.8 ± 4.8** 1.5 ± 0.9 
18.8 73.2 ± 6.9** 59.8 ± 6.7** 1.5 ± 1.0 
37.5 90.3 ± 2.0** 79.8 ± 5.6** 2.0 ± 0.9 
75 93.7 ± 2.9** 87.0 ± 4.1** 2.3 ± 1.2 
150 96.3 ± 1.6** 85.3 ± 5.2** 1.8 ± 1.5 
     
Aspirin 
37.5 55.5 ± 2.9** 1.4 ± 0.9 1.6 ± 1.1 
75 70.3 ± 4.0** 2.1 ± 1.2 1.9 ± 1.5 
150 96.5 ± 3.9** 1.8 ± 0.7 2.2 ± 1.0 
 
The maximal aggregation was recorded (final concentrations of AA  0.35 mmol/L, ADP 3 µmol/L and PAF 7.2 nmol/L). Percentage 
inhibition by drugs was calculated by use of the following equation: Inhibition of aggregation = (A - B) / A ×100. (A is the platelet 
aggregation rate of drugs and B is the platelet aggregation rate of NS control. Values are means ± SD, n = 6, ** P < 0.01, compared 
with saline (platelet aggregation rate of saline: AA 78.0 ± 4.7, ADP 67.5 ± 3.1 and PAF 59.0 ± 2.8). AA, Arachidonic acid; ADP, 
adenosine diphosphate; PAF, platelet-activating factor. 
 
 
free calcium ([Ca2+]i) was (95  ±  13) nmol/L; the [Ca
2+]i 
activated by AA was (313 ± 26) nmol/L. Pretreated with 
polydatin at 75, 150 and 300  mol/L, the resting [Ca2+]i 
were (93 ± 19), (91 ± 18) and (88 ± 15) nmol/L, 
respectively. In the presence of EGTA, the resting [Ca2+]i 
was (73 ± 14) nmol/L, and AA-stimulated [Ca2+]i increase 
was (121 ± 12) nmol/L. AA-elevated [Ca2+]i either in the 
presence of CaCl2 or EGTA was markedly suppressed by 
polydatin. Verapamil significantly lowered [Ca2+]i 
elevation, but it had no influence on the resting [Ca2+]i 
increase (Table 6). 
 
 
Effect of polydatin on rabbit plasma levels of TXB2 
and 6-keto-PGF1 
 
Polydatin at 5, 10 and 20 mg/kg significantly decreased 
plasma TXB2 level and increased plasma 6-keto-
prostaglandin F1 level. Aspirin strongly decreased the 
levels of both TXB2 and plasma 6-keto-prostaglandin F1 
in plasma (Tables 7 and 8).  
 
 
Effect of polydatin on the binding of thrombin-
activated platelets to neutrophils 
 
The percentage of rosettes in saline group was 69.7 or 
13.3% in a condition of external 1 mmol / L CaCl2 or 5 
mmol/L egtazic acid. Polydatin and aspirin significantly 
decreased the binding of platelets to neutrophils with 1 
mmol/L external Ca2+. The IC50 values were 51.9 and 
61.8 µmol/L, respectively (Table 9).  
 
 
Effect of polydatin on platelet aggregation induced by 
the suspension of activated neutrophils 
 
Polydatin markedly inhibited platelet aggregation induced  
 
  









Inhibition of platelet aggregation (%) 
30 min 60 min 90 min 120 min 180 min 240 min 
AA Polydatin 5 60.0 ± 2.4** 74.5 ± 4.2** 78.5 ± 7.3** 58.2 ± 4.8** 48.3 ± 6.1** 45.5 ± 4.1** 
  10 67.2 ± 4.2** 89.7 ± 2.9** 88.2 ± 6.8** 65.5 ± 4.2** 58.8 ± 4.6** 50.8 ± 6.4** 
  20 71.5 ± 4.6** 92.2 ± 2.6** 93.2 ± 2.4** 71.8 ± 6.9** 60.5 ± 3.7** 49.0 ± 6.4** 
        
 Aspirin 10 54.8 ± 8.7** 72.2 ± 9.7** 84.2 ± 6.6** 90.5 ± 4.3** 72.5 ± 7.2** 68.8 ± 6.1** 
        
ADP Polydatin 5 51.3 ± 2.1** 67.3 ± 6.1** 64.0 ± 7.9** 51.3 ± 8.4** 40.2 ± 3.7** 37.5 ± 5.0** 
  10 56.7 ± 3.3** 77.3 ± 2.6** 74.5 ± 5.2** 57.3 ± 5.9** 48.8 ± 3.2** 41.7 ± 6.8** 
  20 65.3 ± 5.3** 79.5 ± 7.4** 70.3 ± 3.8** 62.5 ± 7.2** 53.7 ± 6.1** 45.0 ± 10.1** 
        
 Aspirin 10 7.7 ± 2.2 11.3 ± 3.3 14.8 ± 3.1 16.5 ± 4.9 12.7 ± 3.3 11.5 ± 3.9 
        
PAF Polydatin 5 10.0 ± 2.9 8.3 ± 3.1 9.5 ± 1.9 8.5 ± 2.6 7.7 ± 2.2 6.5 ± 1.9 
  10 11.8 ± 2.5 9.7 ± 2.5 9.2 ± 3.4 11.5 ± 4.0 8.2 ± 2.8 7.0 ± 1.4 
  20 11.5 ± 2.7 12.2 ± 4.0 10.7 ± 3.1 9.7 ± 2.0 7.2 ± 2.6 5.5 ± 1.9 
        
 Aspirin 10 1.8 ± 1.2 3.8 ± 1.5 4.8 ± 2.1 6.2 ± 2.8 4.5 ± 1.9 4.2 ± 2.4 
 
Values are means ± SD, n = 6, *P < 0.05, **P < 0.01, compared with 0 min. Platelet aggregation rate at 0 min (%): AA 73.7 ± 5.6, ADP 64.3 ± 4.6 















Saline - 313 ± 26 121 ± 12 192 ± 14 
     
Polydatin 
75 247 ± 32** 101 ± 10* 136 ± 22** 
150 206 ± 19** 87 ± 14** 119 ± 5** 
300 188 ± 24** 71 ± 11** 107 ± 13** 
     
Verapamil 80 177 ± 20** 119 ± 8 58 ± 12** 
 
Values are means ± SD, n = 6, *P < 0.05, **P < 0.01, compared with saline. AA (200 µmol / L) -stimulated rise in [Ca2+]i was 
measured separately in the presence of 1 mmol/L CaCl2 or egtazic acid. The rise in [Ca2+]i in the presence of CaCl2 1 mmol/L 
represents a combination of Ca2+ release and influx of Ca2+. The rise in the presence of egtazic acid 1 mmol/L reflects Ca2+ 




by the suspension of fMLP-activated neutrophils. The IC50 





Injection of AA caused platelet aggregation in lung, a 
lesser circulation and brought about a decline in the 
breath and blood circulation which eventually induce 
sanimal’s death (Dogné et al., 2004; De Leval et al., 
2004). Polydatin obviously reduced the mortality of mice 
in this model. It is suggested that polydatin showed 
potent inhibition on the activity of AA and TXA2. Electrical 
stimulation thrombosis model is similar to human artery 
thrombosis and has little determinate error (Schumacher 
et al., 1996). Polydatin at 5 mg/kg could significantly 
prolong the occlusion time. It is suggested that polydatin 
showed the activity of anti-artery thrombosis. 
In rat inferior vena ligation model, polydatin at 5, 10 and 
20 mg/kg evidently reduced the wet and dry thrombus 
weight. It is suggested that polydatin prevented against 
the formation of venous thrombosis. In these thrombotic 
models, polydatin showed dose-dependently anti-
thrombotic effects. To confirm its possible mechanisms, a 
 
  




Table 7. Effect of Polydatin on rabbit plasma levels of TXB2 (µg/L). 
 
Group Dose (mg/kg) 0 min 30 min 60 min 120 min 
Saline - 1.69 ± 0.38 1.65 ± 0.32 1.69 ± 0.35 1.61 ± 0.43 
Aspirin 10 1.55 ± 0.40 1.06 ± 0.33* 0.61 ± 0.19** 0.54 ± 0.10** 
      
Polydatin 
5 1.70 ± 0.31 1.46 ± 0.22 1.10 ± 0.27* 0.93 ± 0.09** 
10 1.66 ± 0.27 1.12 ± 0.15* 0.74 ± 0.13** 0.64 ± 0.14** 
20 1.58 ± 0.30 0.93 ± 0.18** 0.58 ± 0.23** 0.41 ± 0.20** 
 




Table 8. Effect of Polydatin on rabbit plasma levels of 6-keto-PGF1 (µg/L). 
 
Group Dose (mg/kg) 0 min 30 min 60 min 120 min 
Saline - 0.59 ± 0.18 0.51 ± 0.20 0.52 ± 0.15 0.57 ± 0.12 
Aspirin 10 0.65 ± 0.14 0.31 ± 0.07** 0.26 ± 0.10** 0.22 ± 0.08** 
      
Polydatin 
5 0.66 ± 0.16 0.65 ± 0.24 1.07 ± 0.29* 1.62 ± 0.25** 
10 0.58 ± 0.26 2.46 ± 0.35** 3.27 ± 0.43** 3.03 ± 0.42** 
20 0.61 ± 0.19 3.17 ± 0.14** 4.05 ± 0.56** 3.62 ± 0.36** 
 




Table 9. Effect of polydatin on the binding of thrombin stimulated 
platelets to neutrophils in rats. 
 
Dose (µmol/L) 
Adhesion rate (%) 
Polydatin Aspirin 
0 67.1 ± 5.8 66.1 ± 7.9 
18.8 61.6 ± 4.4 59.7 ± 3.1 
37.5 41.3 ± 4.1** 41.9 ± 3.8** 
75 28.6 ± 5.2** 33.1 ± 3.4** 
150 23.1 ± 3.4** 22.4 ± 4.6** 
300 15.7 ± 3.8** 13.1 ± 2.4** 
 
Values are means ± SD, n = 6, *P < 0.05, **P < 0.01, compared with 
saline. The percentage of saline group was 69.7 in a condition of external 




Table 10. Effect of polydatin on platelet aggregation stimulated by 
the suspension of fMLP–activated neutrophils in rats. 
 
Dose (µmol/L) 
Platelet aggregation rate (%) 
Polydatin Aspirin 
0 72.3 ± 6.5 70.9 ± 8.2 
37.5 60.1 ± 5.2* 69.7 ± 3.9 
75 51.4 ± 3.5** 65.8 ± 7.2 
150 42.2 ± 8.1** 63.0 ± 10.3 
300 36.4 ± 5.8** 66.2 ± 5.4 
600 29.3 ± 6.9** 64.5 ± 7.5 
 
Values are means ± SD, n = 10, *P < 0.05, **P < 0.01, compared with 
the platelet aggregation rate before drugs were added. 
 
  




series of studies were conducted. Activation and 
aggregation of platelets is an important reason in the 
process of thrombosis. Multiple pathways contribute to 
platelet activation and AA, ADP and PAF are considered 
as the main activating agents in this process (Vargaftig et 
al., 1980). This study confirms that polydatin significantly 
inhibited AA- and ADP-induced platelet aggregation in 
vitro and ex vivo. It is suggested that polydatin may 
selectively affect ADP receptors and cyclooxygenase 
pathway, but do not act on PAF receptors. These results 
indicate that the antithrombotic effects of polydatin may 
be related with its antiplatelet aggregation. 
Activation of blood platelets (including aggregation and 
release) occurs always through an elevation of [Ca2+]i 
(Nesbitt et al., 2003). Influence of polydatin on the 
increase of [Ca2+]i stimulated by AA was measured in this 
investigation. The AA-induced [Ca2+]i increase in the 
presence of CaCl2 was more than that in the absence of 
extracellular Ca2+, suggesting that the major component 
of the AA-induced increase in [Ca2+]i is caused by the 
influx of Ca2+ ions across the plasma membrane. 
Polydatin concentration-dependently lowered the [Ca2+]i 
increase stimulated by AA in the presence of CaCl2 or 
EGTA, respectively. This demonstrated that polydatin 
inhibited both the influx of extracellular calcium and the 
mobilization of calcium from intracellular stores. 
This study shows that polydatin significantly elevated 
plasma level of 6-keto-PGF1 while markedly reducing 
that of TXB2. It is suggested that the mechanism of 
polydatin on inhibiting the metabolism of AA do not be 
restrain of the activity of COX, but due to its modulation 
on PGI2  and TXA2 .  AA can cause rapid formation of 
TXA2 in platelets and TXA2 can stimulate [Ca
2+]i level and 
result in platelet aggregation. Polydatin at the dose range 
that inhibited platelet aggregation and TXB2 formation, 
could significantly suppress [Ca2+]i increase stimulated by 
AA. It is suggested that the antiplatelet effect of polydatin 
may be due to its ability to inhibit Ca2+ elevation. 
Polydat in,  therefore, is different from aspirin both in 
potency and quality of antiplatelet and antithrombosis.  
Neutrophils and platelets, but not platelets alone, are 
closely associated with thromboembolic disorders. 
Interactions of these two kinds of blood cells are involved 
in the process of thrombomodulation (Zhao et al., 2008). 
Platelet-derived products are able to promote neutrophil 
chemotaxsis, enzyme release and phagocytosis, and to 
inhibit oxidative burst. On the other hand, neutrophil-
derived products can enhance platelet aggregation 
(Caron et al., 2002). Thus, it is more advantageous to 
develop an antithrombotic drug especially at an angle of 
influencing multiple cellular interactions. Thrombus 
formation is mediated by the platelet-neutrophil inter-
actions including cell binding and platelet aggregation 
(Wetterö et al., 2003). Clinical studies showed that 
platelet-neutrophil rosette in patients with thrombotic 





2004). Polydatin showed significant inhibition on rosetting 
between thrombin-activated platelets and neutrophils. 
Polydatin also exerted a concentration-dependent inhi-
bitory effect on platelet aggregation induced by the super-
natant from fMLP-activated neutrophils. It is suggested 
that polydatin showed potent antithrombotic activity also 
due to its influence on platelet-neutrophil interactions. 
Taken together, these results suggest that polydatin has 
the potential to become a useful antiplatelet and 
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